Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12028MR)

This product GTTS-WQ12028MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12028MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7053MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ10249MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ15314MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ10415MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ785MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ5542MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ10963MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ12800MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-59R5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW